The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization

Mucosal Immunology

Volumn 6, Issue 6, 2013, Pages 1168-1178

  Fang, Y ^a,b   Zhang, T ^c   Lidell, L ^a   Xu, X ^c   Lycke, N ^a   Xiang, Z ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CTA1 DD; IMMUNOGLOBULIN G; PROTEIN FCGAMMARIIIA; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CONNECTIVE TISSUE CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN PAPILLOMAVIRUS TYPE 16; MAST CELL; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; VAGINAL SECRETION; VIRUS IMMUNITY; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CELL DEGRANULATION; CELL LINE; CHOLERA TOXIN; CONNECTIVE TISSUE; HUMANS; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NASAL MUCOSA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; VIRAL VACCINES;

EID: 84885977192     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.16     Document Type: Article

References (62)

1. Lycke, N. Recent progress in mucosal vaccine development: Potential and limitations. Nat. Rev. Immunol. 12, 592-605 (2012).
2. Brandtzaeg, P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25, 5467-5484 (2007).
3. Guy, B. The perfect mix: Recent progress in adjuvant research. Nat. Rev. Microbiol. 5, 505-517 (2007).
4. McKee, A.S., Munks, M.W. & Marrack, P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27, 687-690 (2007).
5. Lambrecht, B.N., Kool, M., Willart, M.A. & Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21, 23-29 (2009).
6. van Ginkel, F.W. et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect. Immun. 73, 6892-6902 (2005).
7. Svennerholm, A.M. From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. Indian J. Med. Res. 133, 188-196 (2011).
8. McLachlan, J.B. et al. Mast cell activators: A new class of highly effective vaccine adjuvants. Nat. Med. 14, 536-541 (2008).
9. McGowen, A.L., Hale, L.P., Shelburne, C.P., Abraham, S.N. & Staats, H.F. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 27, 3544-3552 (2009).
10. Staats, H.F. et al. Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One 6, e16532 (2011).
11. Agren, L.C., Ekman, L., Lowenadler, B., Nedrud, J.G. & Lycke, N.Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162, 2432-2440 (1999).
12. Lycke, N. & Bemark, M. Mucosal adjuvants and long-Term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol. 3, 556-566 (2010).
13. Bemark, M. et al. A unique role of the cholera toxin A1-DD adjuvant for long-Term plasma and memory B cell development. J. Immunol. 186, 1399-1410 (2011).
14. Mattsson, J. et al. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. J. Immunol. 187, 3641-3652 (2011).
15. Agren, L.C., Ekman, L., Lowenadler, B. & Lycke, N.Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158, 3936-3946 (1997).
16. Fang, Y., Larsson, L., Mattsson, J., Lycke, N. & Xiang, Z. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation. J. Immunol. 185, 2935-2941 (2010).
17. Brown, J.M., Wilson, T.M. & Metcalfe, D.D. The mast cell and allergic diseases: Role in pathogenesis and implications for therapy. Clin. Exp. Allergy 38, 4-18 (2008).
18. Tsujimura, Y. et al. Basophils play a pivotal role in immunoglobulin-Gmediated but not immunoglobulin-E-mediated systemic anaphylaxis. Immunity 28, 581-589 (2008).
19. Ujike, A. et al. Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-Affinity Fc receptors for IgG. J. Exp. Med. 189, 1573-1579 (1999).
20. Ovary, Z. Passive cutaneous anaphylaxis in the mouse. J. Immunol. 81, 355-357 (1958).
21. Braga, F. & Mota, I. Homologous passive cutaneous anaphylaxis (PCA) in mice and heterologous PCA induced in rats with mouse IgE. Immunology 30, 655-669 (1976).
22. Malbec, O. & Daeron, M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol. Rev. 217, 206-221 (2007).
23. Hiraoka, S. et al. Fc receptor beta subunit is required for full activation of mast cells through Fc receptor engagement. Int. Immunol. 11, 199-207 (1999).
24. Moon, T.C. et al. Advances in mast cell biology: New understanding of heterogeneity and function. Mucosal Immunol. 3, 111-128 (2010).
25. Latour, S., Bonnerot, C., Fridman, W.H. & Daeron, M. Induction of tumor necrosis factor-Alpha production bymast cells via Fc gamma R. Role of the Fc gamma RIII gamma subunit. J. Immunol. 149, 2155-2162 (1992).
26. Ekoff, M., Strasser, A. & Nilsson, G. FcepsilonRI aggregation promotes survival of connective tissue-like mast cells but not mucosal-like mast cells. J. Immunol. 178, 4177-4183 (2007).
27. Welle, M. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J. Leukoc. Biol. 61, 233-245 (1997).
28. Kitamura, Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Annu. Rev. Immunol. 7, 59-76 (1989).
29. Young, J.D., Liu, C.C., Butler, G., Cohn, Z.A. & Galli, S.J. Identification, purification, and characterization of a mast cell-Associated cytolytic factor related to tumor necrosis factor. Proc.Natl. Acad. Sci. USA 84, 9175-9179 (1987).
30. Theoharides, T.C. et al. Chondroitin sulphate inhibits connective tissue mast cells. Br. J. Pharmacol. 131, 1039-1049 (2000).
31. Gersch, C. et al. Mast cells and macrophages in normal C57/BL/6 mice. Histochem. Cell Biol. 118, 41-49 (2002).
32. Mrabet-Dahbi, S., Metz, M., Dudeck, A., Zuberbier, T. & Maurer,M.Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Exp. Dermatol. 18, 437-444 (2009).
33. Dessy, F.J. et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccinationwith the AS04-Adjuvanted HPV-16/18 cervical cancer vaccine. Hum. Vaccin. 4, 425-434 (2008).
34. Zhang, T. et al. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPVtype58can elicit highlevel ofhumoral immunity but also induce immune interference among component types. Vaccine 28, 3479-3487 (2010).
35. Abraham, S.N. & St John, A.L. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 10, 440-452 (2010).
36. Galli, S.J. & Tsai, M. Mast cells in allergy and infection: Versatile effector and regulatory cells in innate and adaptive immunity. Eur. J. Immunol. 40, 1843-1851 (2010).
37. Galli, S.J., Nakae, S. & Tsai, M. Mast cells in the development of adaptive immune responses. Nat. Immunol. 6, 135-142 (2005).
38. Galli, S.J., Grimbaldeston, M. & Tsai, M. Immunomodulatory mast cells: Negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 8, 478-486 (2008).
39. Jawdat, D.M., Rowden, G. Marshall, J.S.Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J. Immunol. 177, 1755-1762 (2006).
40. Suto, H. et al. Mast cell-Associated TNF promotes dendritic cell migration. J. Immunol. 176, 4102-4112 (2006).
41. Heib, V. et al. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 110, 946-953 (2007).
42. Shelburne, C.P. et al. Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host Microbe 6, 331-342 (2009).
43. Dawicki, W., Jawdat, D.W., Xu, N. & Marshall, J.S. Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J. Immunol. 184, 2116-2123 (2010).
44. Lobell, R.B., Arm, J.P., Raizman, M.B., Austen, K.F. & Katz, H.R. Intracellular degradation of Fc gamma RIII in mouse bone marrow culture-derived progenitor mast cells prevents its surface expression and associated function. J. Biol. Chem. 268, 1207-1212 (1993).
45. Stanovnik, L., Logonder-Mlinsek, M. & Erjavec, F. The effect of compound 48/80 and of electrical field stimulation on mast cells in the isolated mouse stomach. Agents Actions 23, 300-303 (1988).
46. Enerback, L. & Lowhagen, G.B. Long term increase of mucosal mast cells in the rat induced by administration of compound 48/80. Cell Tissue Res. 198, 209-215 (1979).
47. Matsushima, H., Yamada, N., Matsue, H. & Shimada, S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J. Immunol. 173, 531-541 (2004).
48. Nimmerjahn, F. & Ravetch, J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
49. Roopenian, D.C. & Akilesh, S. FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725 (2007).
50. Bitonti, A.J. & Dumont, J.A. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv. Drug Deliv. Rev. 58, 1106-1118 (2006).
51. Ugwoke, M.I., Agu, R.U., Verbeke, N. & Kinget, R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 57, 1640-1665 (2005).
52. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine 25 (Suppl 3), C1-230 (2007).
53. Revaz, V. et al. Humoral and cellular immune responses to airway immunization ofmice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res. 76, 75-85 (2007).
54. Sasagawa, T. et al. A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res. 110, 81-90 (2005).
55. Nardelli-Haefliger, D. et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23, 3634-3641 (2005).
56. Nardelli-Haefliger, D. et al. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J. Virol. 73, 9609-9613 (1999).
57. Hunter, Z., Tumban, E., Dziduszko, A. & Chackerian, B. Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses. Vaccine 29, 4584-4592 (2011).
58. Wira, C., Fahey, J.,Wallace, P. & Yeaman, G. Effect of the menstrual cycle on immunological parameters in the human female reproductive tract. J. Acquir. Immune Defic. Syndr. 38 (Suppl 1), S34-S36 (2005).
59. Kaushic, C., Ashkar, A.A., Reid, L.A. & Rosenthal, K.L. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J. Virol. 77, 4558-4565 (2003).
60. Dudeck, A., Suender, C.A., Kostka, S.L., von Stebut, E. & Maurer,M. Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur. J. Immunol. 41, 1883-1893 (2011).
61. Xiang, Z. & Nilsson, G. IgE receptor-mediated release of nerve growth factor by mast cells. Clin. Exp. Allergy 30, 1379-1386 (2000).
62. Xiang, Z., Moller, C. & Nilsson, G. Readministration of IgE is required for repeated passive cutaneous anaphylaxis in mice. Int. Arch. Allergy Immunol. 141, 168-171 (2006).